RepliCel Announces Closing of Private Placement
RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF and CNSX: RP) is pleased to announce the closing of a private placement financing (the “Financing”), pursuant to which it has...
View ArticleRepliCel Receives Issue Notification from the United States Patent and...
VANCOUVER, BC – April 18, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX:RP) is pleased to announce that it has received issue notification from the United States...
View ArticleVancouver Biotech Receives U.S. Patent for Hair Regeneration Technology
By Emma Crawford, Thu Apr 18, 2013 10:53am PST Vancouver biotech RepliCel Life Sciences Inc. (OTCBB:REPCF)(CNSX:RP) has received a United States patent for its technology related to hair regeneration,...
View ArticleRepliCel Announces New Tendon Repair Technology Based on its Hair Follicle...
VANCOUVER, BC – April 30, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CDNX:RP) is pleased to announce that it is initiating the clinical development of a new...
View ArticleRepliCel’s Chief Scientific Officer Updates World Congress for Hair Research...
VANCOUVER, BC – May 3, 2013 – RepliCel Life Sciences Inc.(the “Company” or “RepliCel”) (OTCBB: REPCF) (CDNX: RP) reports that its Chief Scientific Officer, Dr. Kevin McElwee, will be presenting at the...
View ArticleRepliCel Presents Further Clinical Data and Corporate Update at its Annual...
June 11, 2012 – Vancouver, British Columbia – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB:REPCF) presented significant new data from its Phase I/IIa first-in-man clinical trial at...
View ArticleRepliCel Announces Closing of Private Placement
VANCOUVER, BC – May 21, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF and CNSX: RP) is pleased to announce the closing of a private placement financing (the...
View ArticleRepliCel Annual General Meeting Notice
RepliCel Life Sciences Inc. will be hosting its Annual Meeting of Shareholders on Thursday, May 30, 2013. David Hall, CEO and Prof. Rolf Hoffmann, Chief Medical Officer, will give a 20 minute...
View ArticleDr. Jerry Shapiro to Present RepliCel Data to European Academy of Dermatology...
RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CDNX: RP) reports that one of its founders, Dr. Jerry Shapiro, MD, FRCPC, will be presenting RepliCel’s Phase I safety data and...
View ArticleRepliCel and Shiseido Announce Collaboration and Technology Transfer...
Tokyo, Japan and Vancouver, Canada – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX:RP) and Shiseido Company, Limited (“Shiseido”) (Tokyo Stock Exchange Code: 4911) (ADR...
View ArticleReplicel and Shiseido Complete Collaboration and Technology Transfer...
Vancouver, Canada – July 11, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX:RP) is pleased to report that it has completed the previously announced Collaboration...
View ArticleRepliCel Announces Closing of Private Placement
RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF and CNSX: RP) is pleased to announce the closing of a private placement financing (the “Financing”), pursuant to which it has...
View ArticleRepliCel Retains Westwicke Partners as Investor Relations Counsel
RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies, today announced that it has retained Westwicke...
View ArticleRepliCel Announces Stock Option Grant
VANCOUVER, BC – September 6, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies, announces...
View ArticleStem Cell Technology Used in Search for the Holy Grail of Hair Treatments: a...
Hisae Nakamura, director of research and development for RepliCel, with a device used to inject cells into the scalp to stimulate hair growth. The company’s process replicates cells from hair follicles...
View ArticleRepliCel Forms Clinical Advisory Board to Support the Development of RCT-01...
RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP), a clinical stage biopharmaceutical company focused on the development of autologous cell therapies for regenerative medicine, today announced the...
View ArticleA cure for baldness? Stem cell researchers race to regenerate follicles from...
The cure for baldness? It could be closer than you think — i.e. among the baldness-proof follicles that usually reside at the bottom back of the head, stem cell researchers claim. Erin Ellis, Postmedia...
View ArticleRepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate...
VANCOUVER, BC – November 20, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today...
View ArticleRepliCel Reports Progress on Shiseido Technology Transfer for RCH-01...
Vancouver, Canada – December 19, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP) today reported on the progress of its technology transfer agreement with its partner, Shiseido Company,...
View ArticleRepliCel Announces Conditional Approval from TSX Venture Exchange
VANCOUVER, BC – January 2, 2014 –RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (CNSX: RP) is pleased to announce that it has received conditional approval from the TSX...
View Article
